Chronic Kidney Disease (CKD) significantly alters the pharmacokinetics and pharmacodynamics of many drugs, making medication management a critical aspect of patient care. In the context of dialysis access procedures—such as central venous catheter insertion or arteriovenous fistula placement—drug safety becomes even more paramount. This article synthesizes key recommendations and evidence-based practices from the...
Nutrivigilance is the systematic monitoring, assessment, and prevention of adverse effects related to the use of food supplements, fortified foods, and other nutritional products. It is the pharmacovigilance equivalent for the nutraceutical and functional food sector.
This document is the "EDA Renal Anaemia Guidance to Good Pharmacy Practice" (Code: EDREX:GU.CAP.Care.016, Version: 2025), issued by the Egyptian Drug Authority's Central Administration of Pharmaceutical Care. It serves as a comprehensive, evidence-based clinical practice guideline for the management of anemia in patients with Chronic Kidney Disease (CKD).
The health-related SDGs are a subset of the United Nations’ 17 Sustainable Development Goals (2015–2030) that specifically focus on improving global health outcomes. They are tracked under SDG 3: “Ensure healthy lives and promote well-being for all at all ages”, but also include health-related indicators from other SDGs (e.g., clean water, nutrition, gender equality).
In the realm of patient safety, the spotlight often shines on pharmacovigilance—the science of monitoring drug side effects. However, a parallel and equally critical discipline operates in the shadows: Medical Device Vigilance.
This is a fundamental concept in pharmacovigilance (drug safety monitoring). Let's break down the Important Medical Event (IME) List from MedDRA with a clear illustration.
This document is an official guidance from the U.S. Food and Drug Administration (FDA) issued in December 2025. It provides the agency's current recommendations and interpretations on how clinical investigators (the doctors/researchers running clinical trials) should handle safety reporting for drugs and medical devices that are still under investigation.
Advancing Medication Safety Through Knowledge and Vigilance
